Connect with us!
Like us!
Follow us!

Achieving unmet medical
needs and enhancing
consumer benefits.

Rubicon Research has developed several proprietary drug delivery technologies with secured IP protection such as:

RubiERT®

Application area: Modified release

  • Combines non-swelling pH dependent and pH independent release retardants
  • Non-swelling nature of the dosage form can reduce plateau in the release profile and allows for complete release of the drug
  • Drug molecule experiences reduced diffusion path-length compared to swelling systems
  • Due to non-swelling nature a more predictable GI transit time is expected
  • Candidate molecules: Tramadol, Ropinirole

Contact us: Email us at bd@rubicon.co.in if your product needs a unique release profile.

RubiReten®

Application area: Gastric retention

  • Gastroretentive Platform Technology for delivery of active agents with poor solubility and window of absorption in a controlled release manner
  • Combines the concepts of solubilization and gastro-retention
  • The solubilized drug is released slowly and continuously to trickle across the absorption window to maximize its absorption

Candidate molecules: Valsartan, Pregabalin

Contact us: Email us at bd@rubicon.co.in if your product requires absorption in the upper part of the gastrointestinal tract (GIT).

RubiSRL®

Application area: Controlled release liquids abuse resistance

  • Combination of two controlled release technologies: Ion exchange and membrane diffusion control
  • The medication release from the Pennkinetic System is precise and unaffected by ph variations, temperature or contents in the stomach and intestine

Candidate molecules: Dextromethorphan Polistirex, Methylphenidate

Contact us: Email us at bd@rubicon.co.in if your liquid product requires a controlled release profile.

RubiDT®

Application area: Instant dispersions with taste masking

  • Employs high viscosity polymer
  • Reduces the movement of particles, thereby ensuring uniformity of the drug content
  • Unique feature of the technology is the rapid disintegration with retarded sedimentation rate
  • Reduction in variability of response

Candidate molecules: Diclofenac, Linezolid, Azithromycin, Calcium Citrate, Calcium Orotate, Sildenafil Citrate

Contact us: Email us at bd@rubicon.co.in if your product needs a taste-masked solution in an alternate dosage format or you are pursuing a product for populations with dysphagia (pediatric and geriatric).

Apart from the above technologies, Rubicon Research’s experience involves working with Barrier Membrane Technology, Matrix Systems, and Osmotic Systems. Reach out to us to have a conversation about your drug development needs. We work from the first principles of science to develop custom-made solutions because we understand that every problem is unique.

By leveraging our R&D infrastructure and ecosystem, we can take your product to clinic and to the market at the earliest.